OCRX Ocera Therapeutics Inc.

0.96
+0.00  (0%)
Previous Close 0.96
Open 0.96
Price To book 2.74
Market Cap 25449649
Shares 26,510,051
Volume 64,414
Short Ratio 10.54
Av. Daily Volume 141,558

SEC filingsSee all SEC filings

  1. 8-K - Current report 171008964
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17996990
  3. 8-K - Current report 17996828
  4. 8-K - Current report 17925463
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released January 30, 2017 - primary endpoint not met. Plans to meet with FDA 3Q 2017 - noted March 8, 2017.
OCR-002 (IV)
Hepatic encephalopathy
Phase 2a trial initiation announced June 1, 2017. Top-line data due by the end of 2017.
OCR-002
Cirrhosis